195 West Street
About PAREXEL International
THE CLEAREST PATH TO CAREER FULFILLMENT STARTS WITH PAREXEL.
At PAREXEL, the best minds in the industry are simplifying the journey from science to new treatments—and getting them into the hands of those who need them most. If you join us, you can be a part of that. Through innovative processes and technology, your journey with us will not only be challenging but truly rewarding. PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.
PAREXEL Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates approximately 75 locations in over 50 countries around the world, and has more than 15,000 employees. For more information about PAREXEL International, visit www.PAREXEL.com.
472 articles with PAREXEL International
Josef von Rickenbach will step down as Chairman of the Board of Directors effective December 31, 2018.
The program will bring high-value training opportunities to China’s clinical trial sites and investigators, enhancing the execution of local clinical trials and driving innovation in China’s biopharmaceutical industry.
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
Today announced the appointment of new members to the Board of Directors following Pamplona Capital Management’s acquisition in September 2017.
PAREXEL Navigates China’s Complex Drug Development and Market Landscape for Global Biopharmaceutical Companies with New China Advisory Service
The offering leverages PAREXEL’s deep experience with and knowledge of the Chinese biopharmaceutical landscape to help companies navigate all aspects of the country’s drug development process.
Solutions Built on the Perceptive Cloud Platform Leverage Mobile and Wearable Technology
PAREXEL Advances Patient-Centric Drug Development with Introduction of Its Patient Innovation Center
The Center can help sponsors improve the drug development process by reducing the practical, financial and geographical barriers patients and caregivers often face, and optimize patient involvement and engagement.
PAREXEL International Corporation announced that Xavier Flinois, President of PAREXEL Informatics, has been named to PharmaVOICE magazine’s list of the 100 most inspiring people in the life sciences industry.
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.
PAREXEL to Lead Discussions on Global Drug Development, Unveil New Industry Research at DIA Annual Meeting
PAREXEL International Corporation announced today that several of its experts will discuss key issues facing the industry at the 54th Drug Information Association (DIA) Annual Meeting
PAREXEL International Corporation announced that the Company has received recognition for its service and expertise from several notable industry organizations.
Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company's Board of Directors effective May 1, 2018.
University of Texas System Initiative, Clinical Trials Xpress (CTX), Named as a PAREXEL Strategic Site Alliance Network Member
Clinical Trials Xpress has been named by PAREXEL, the world's leading innovator of biopharmaceutical services, as a member of its Global Site Alliance Network.
Proven Healthcare Industry Leader will head PAREXEL’s Commercial Strategy
PAREXEL’s Randomization and Trial Supply Management Service Recognized as Leader in Second Consecutive Industry Standard Research Benchmark Report
PAREXEL’s ClinPhone® Randomization and Trial Supply Management cited as the most preferred and widely used Interactive Response Technology solution
PAREXEL and Meiji Pharmaceutical University Announce Academic Program to Develop Japan’s Biopharmaceutical Workforce
Joint Program for Clinical Research and Clinical Trial Management to be offered through the PAREXEL Academy
Comprehensive end-to-end services enable effective, streamlined communication with key stakeholders across all stages of drug development and commercialization
Collaboration combines best-in-class offerings from CHA and PAREXEL to enhance early phase clinical trials in growing hub for drug development
After 35 years at the helm of Parexel International Corporation, co-founder Josef von Rickenbach is stepping down from his role as chief executive officer.
PAREXEL International Corporatio announced the appointment of Jamie Macdonald as Chief Executive Officer (CEO) effective March 15, 2018.